Brief: Shattuck Labs Announces Phase 2 Clinical Trial Of Sl-325 In Hidradenitis Suppurativa And Appointment Of Shoba Ravichandran, M.D., As Senior Vice President, Clinical Development
01/10/2026 12:04
BRIEF-Shattuck Labs Announces Phase 2 Clinical Trial Of Sl-325 In Hidradenitis Suppurativa And Appointment Of Shoba Ravichandran, M.D., As Senior Vice President, Clinical Development Oct 1 (Reuters) - Shattuck Labs Inc STTK.O:
SHATTUCK LABS ANNOUNCES PHASE 2 CLINICAL TRIAL OF SL-325 IN HIDRADENITIS SUPPURATIVA AND APPOINTMENT OF SHOBA RAVICHANDRAN, M.D., AS SENIOR VICE PRESIDENT, CLINICAL DEVELOPMENT
SHATTUCK LABS - TO INITIATE PHASE 2 TRIAL OF SL-325 IN HIDRADENITIS SUPPURATIVA
SHATTUCK LABS - PHASE 2 TRIAL TO START IN 2026; 16-WEEK DATA EXPECTED IN H1 2028
SHATTUCK LABS - EXISTING CASH EXPECTED TO FUND OPERATIONS INTO 2029
SHATTUCK LABS - IND SUBMISSION FOR PHASE 2 TRIAL EXPECTED IN OCTOBER 2026
Source text: ID:nGNX7fxQPL
Further company coverage: STTK.O
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Shattuck Labs
See all newsBrief: Shattuck Labs Announces Phase 2 Clinical Trial Of Sl-325 In Hidradenitis Suppurativa And Appointment Of Shoba Ravichandran, M.D., As Senior Vice President, Clinical Development
Shattuck Labs Inc reports results for the quarter ended June 30 - Earnings Summary
U.S. STOCKS ON THE MOVEX-Abbott, Columbia Financial, Jabil
U.S. STOCKS ON THE MOVEX-Abbott, Columbia Financial, Jabil,
U.S. STOCKS ON THE MOVE-Duke Energy, Sea, Cardinal Health